I'd like to hear from Bear on the accuracy of this statement.

"RVX did find plaque regression in a big way in the RVX-208 + rosuvastatin cohort of the trial"

If that is true perhaps Resverlogix should have pursued that angle going forward after ASSURE with MACE as a secondary measure.

I believe I did raise that combination in the past. ABL would be a truer blockbuster drug. :o) 

IMO...Koo